CD274 and neoplasm: An exploratory study administered this modified virus (Delta-24-RGDOX or DNX2440) with a PD-L1 inhibitor and noted an increase in infiltrative T cells in vivo in a preclinical tumor model, leading to the initiation of a phase I clinical trial (see Table 1) [128].